Risankizumab (Skyrizi®) therapy for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams38191
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program.
Halifax, NS:
Nova Scotia Health Authority
, 2023.
- Pamphlet Number
- 2345
- Available Online
- View Pamphlet
Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2023
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (9 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Specialty
- Gastrointestinal System
- Medications
- Abstract
- Risankizumab is a biologic medication. A biologic medication is a type of medication that treats inflammation. This pamphlet explains how risankizumab works, how it is given, and how long you can expect to take it. Precautions, side effects, and what to expect after treatment are explained. Side effects that require contacting your primary health care provider are listed.
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 2345
